EUVIMEDOpdag EUVIMED
Crossref

Cytokine Profiling of Erythroderma Biopsies Reveals Types 2 and 17 Immune Activation Status

Tatsiana Pukhalskaya, Mitchell Finkelstein, Dacia A Miyake-Caballero, Michael T Tetzlaff, Jeffrey P North iD, Jarish N Cohen iD

Journal of Cutaneous Pathology · 2025

DOI: 10.1111/cup.14775 ↗

At a glance

Journal article in Journal of Cutaneous Pathology, 2025. Written by Tatsiana Pukhalskaya and 5 co-authors. Institution: Department of Dermatology and Pathology, University of California, California, USA. Major MEDLINE topics: Dermatitis, Exfoliative, Interleukin-13, Cytokines. Cited 2 times so far (Crossref); 45 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Erythroderma is a dermatologic condition characterized by widespread red and scaly skin. The causes include, but are not limited to, psoriasis, eczema, drug eruptions, pityriasis rubra pilaris (PRP), and cutaneous T‐cell lymphoma. Most of these are typified by Type 2 (e.g., eczema) or Type 17 (e.g., psoriasis) immune activation. However, since the clinicopathologic features of erythroderma can be nonspecific, assays that determine the underlying immune activation status are desirable.

Methods

IL‐13 RNA in situ hybridization and IL‐36 immunohistochemistry were performed on 30 specimens of erythroderma, to ascertain Type 2 and Type 17 immune signatures, respectively.

Results

Specimens of erythrodermic psoriasis and PRP showed strong expression of IL‐36 and less than one IL‐13‐positive cell per millimeter. Conversely, those of spongiotic dermatitis showed low expression of IL‐36 and greater than one IL‐13‐positive cell per millimeter. Most specimens of spongiotic, psoriasiform dermatitis demonstrated low IL‐36 expression and greater than one IL‐13‐positive cell per millimeter, but a subset showed high IL‐36 expression and greater than one IL‐13‐positive cell per millimeter.

Conclusions

We developed a Type 2/17 immune signature classifier based on cytokine profiling, which showed that cases of erythroderma fall within distinct categories of immune activation. This categorization may have utility in guiding clinical decisions.

Subjects

MeSH terms (MEDLINE)

Dermatitis, ExfoliativeInterleukin-13CytokinesHumansBiopsyMalePsoriasisFemaleInterleukin-1ImmunohistochemistryMiddle AgedAdultAged

Author keywords

IL‐13IL‐36erythrodermapsoriasisspongiotic dermatitis

Substances

Interleukin-1Interleukin-13interleukin 36, humanCytokines

Authors and institutions

  • Department of Dermatology and Pathology, University of California, California, USA.
  • Cooper Medical School of Rowan University, Camden, New Jersey, USA.

ORCID profiles: Jeffrey P North, Jarish N Cohen

Cite

APA

Pukhalskaya, T., Finkelstein, M., Miyake-Caballero, D. A., Tetzlaff, M. T., North, J. P., & Cohen, J. N. (2025). Cytokine Profiling of Erythroderma Biopsies Reveals Types 2 and 17 Immune Activation Status. Journal of Cutaneous Pathology. https://doi.org/10.1111/cup.14775

Vancouver

Pukhalskaya T, Finkelstein M, Miyake-Caballero DA, Tetzlaff MT, North JP, Cohen JN. Cytokine Profiling of Erythroderma Biopsies Reveals Types 2 and 17 Immune Activation Status. Journal of Cutaneous Pathology. 2025. doi:10.1111/cup.14775

BibTeX
@article{Pukhalskaya2025,
  author = {Pukhalskaya, Tatsiana and Finkelstein, Mitchell and Miyake-Caballero, Dacia A and Tetzlaff, Michael T and North, Jeffrey P and Cohen, Jarish N},
  title = {Cytokine Profiling of Erythroderma Biopsies Reveals Types 2 and 17 Immune Activation Status},
  journal = {Journal of Cutaneous Pathology},
  year = {2025},
  doi = {10.1111/cup.14775}
}
Start for free →